

KESIMPTA - How does KESIMPTA work

[Prescribing information](#)

Image



Image



How does KESIMPTA®▼ (ofatumumab) work?

KESIMPTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features.¹

For full safety information, please refer to the [KESIMPTA Summary of Product Characteristics \(SmPC\)](#).¹

KESIMPTA has been shown to act on B-cells in MS patients, targeting them and inducing cell lysis.¹ KESIMPTA is an anti-CD20 monoclonal immunoglobulin G1 (IgG1) antibody that

selectively targets and binds to the CD20 protein.¹ This protein is expressed on the surface of the majority of B-cells, making it a valuable target for precise MS treatment.² KESIMPTA is thought to work by selectively binding to sites on both the small and the large extracellular loops of CD20 protein on B-cells.²⁻⁴

The precise mechanism of action by which KESIMPTA exerts its therapeutic effects is unknown.

To learn about how KESIMPTA targets B-cell subsets that facilitate inflammation, and how it causes CD20-inducing lysis of these B-cells, watch this short video.¹



VIDEO

CD, cluster of differentiation; IgG, immunoglobulin G; MS, multiple sclerosis; RMS, relapsing multiple sclerosis.

References:

1. KESIMPTA (ofatumumab) Summary of Product Characteristics.
2. Zhang B. *mAbs* 2009;1(4):326–331.
3. Gupta IV & Jewell RC. *Ann N Y Acad Sci* 2012;1263:43–56.
4. Martin R, et al. *Eur J Immunol* 2016;46:2078–2090.

Image

Safety profile

UK | April 2025 | FA-11381598

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email medinfo.uk@novartis.com or call 01276 698370.

Source URL:

<https://www.pro.novartis.com/uk-en/medicines/neuroscience/kesimpta/moa/mechanism-video>